Spotlight
Video

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses phase 3 clinical trials of atezolizumab, an anti-PD-L1 monoclonal antibody, compared with standard chemotherapy in PD-L1-selected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC).

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 01/27/16
Added : 2 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.